Lyka Labs
Lyka Labs Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Lyka Labs Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Lyka Labs Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Lyka Labs Ltd, switchable between annual and quarterly views, consolidated or standalone.
Lyka Labs Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹248.05 Cr and reported EPS of ₹-2.81.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 61 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 |
| Other Income | 2 | 2 | 3 | 2 | 2 | 3 | 1 | 2 | 3 |
| Total Income | 63 | 73 | 65 | 88 | 196 | 96 | 113 | 141 | 132 |
| Cost of Goods Sold (COGS) | 29 | 39 | 36 | 38 | 53 | 38 | 45 | 56 | 50 |
| Gross Profit | 31 | 32 | 26 | 48 | 141 | 56 | 66 | 83 | 78 |
| +Operating Expenses | 36 | 33 | 29 | 29 | 40 | 39 | 51 | 65 | 82 |
| EBITDA | -5 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -3 |
| +Non-Operating Expenses | 21 | 13 | -5 | 33 | 31 | 19 | 17 | 9 | 12 |
| Profit Before Tax (PBT) | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | -12 |
| +Tax Expense | -1 | -9 | 1 | -4 | 21 | -0 | 2 | 3 | -1 |
| Profit After Tax (PAT) | -19 | -6 | -63 | -12 | 39 | -13 | -3 | 8 | -10 |
| Earnings Per Share (EPS) | -6.12 | -2.26 | -21.10 | -4.03 | 13.59 | -4.30 | -0.79 | 2.24 | -2.81 |
| Diluted Shares Outstanding (Nos.) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| +Additional Disclosures | 112 | 126 | 127 | 139 | 184 | 140 | 158 | 185 | 193 |
| Sales Growth % | — | 16.77 | -13.23 | 40.44 | 125.02 | -52.05 | 19.47 | 24.55 | -7.26 |
| YoY Sales Growth % | — | 16.77 | -13.23 | 40.44 | 125.02 | -52.05 | 19.47 | 24.55 | -7.26 |
| Material Cost % | 30 | 21 | 22 | 14 | 14 | 25 | 29 | 27 | 25 |
| Employee Cost % | 28 | 21 | 23 | 17 | 9 | 20 | 24 | 25 | 33 |
| Other Cost % | 32 | 26 | 25 | 16 | 11 | 22 | 21 | 22 | 31 |
| OPM % | -9 | -3 | -6 | 23 | 52 | 18 | 14 | 13 | -3 |
| Tax % | 5 | 59 | -1 | 29 | 35 | 0 | -181 | 29 | 11 |
| Profit Growth % | — | 66.58 | -885.72 | 81.55 | 437.53 | -133.72 | 80.08 | 402.74 | -231.54 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Additional Fields | -16 | -9 | -12 | 11 | 84 | 3 | 3 | 11 | -12 |
Lyka Labs segment analysis: revenue and profit mix.
Disclosed business segments at Lyka Labs with their share of revenue and profit, switchable between consolidated and standalone reporting.
Lyka Labs discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Lyka Labs Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Lyka Labs Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Lyka Labs Ltd's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding has significantly increased from 47.80% in June 2022 to 58.16% by September 2025, indicating strong confidence from the management in the company's future prospects and stability.
The company maintains a healthy financial structure with a low debt-to-equity ratio of 0.38, indicating prudent financial management and reduced reliance on external borrowings, which is positive for long-term stability.
Lyka Labs has demonstrated positive quarterly sales growth, with a 9.70% increase in sales for the latest reported quarter, reflecting a growing demand for its products and effective market penetration strategies.
The company exhibits a respectable operating profit margin (OPM) of 12.70%, showcasing its ability to manage operational costs effectively and generate healthy profits from its core business activities.
Operating within the robust Pharmaceuticals industry, Lyka Labs can capitalize on increasing global healthcare demand, expanding markets, and advancements in medical research to drive future growth.
What can break it.
Lyka Labs trades at a relatively high Price-to-Earnings (P/E) ratio of 45.00, which is higher than several industry peers, suggesting that the stock might be overvalued compared to its current earnings.
The company experienced a substantial decline in quarterly profit, with a -35.40% variation in net profit for the latest quarter, raising concerns about recent profitability and operational efficiency.
Investors seeking income may find the company less attractive due to its 0.00% dividend yield, indicating that Lyka Labs currently does not distribute profits to shareholders through dividends.
The stock is currently trading near its 52-week low of 90.20, significantly below its 52-week high of 177.00, indicating recent poor market performance and potential investor apprehension.
The company's Return on Equity (ROE) of 9.31% and Return on Capital Employed (ROCE) of 9.91% are considerably lower than many industry peers, suggesting suboptimal capital utilization.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Lyka Labs Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Lyka Labs Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Lyka Labs Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Lyka Labs Ltd — derived from the live tape, not yesterday's close.
Lyka Labs Ltd last traded at ₹69.6 with an intraday range of ₹68.3–₹71.49 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹69.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 77.67 | +8.07 | +11.60% |
| R3 | 74.48 | +4.88 | +7.02% |
| R2 | 72.99 | +3.39 | +4.87% |
| R1 | 71.29 | +1.69 | +2.43% |
| PIVOT | 69.80 | 0.20 | 0.28% |
| CURRENT | 69.60 | — | — |
| S1 | 61.72 | -7.88 | -11.32% |
| S2 | 64.91 | -4.69 | -6.73% |
| S3 | 66.61 | -2.99 | -4.30% |
| S4 | 68.10 | -1.50 | -2.15% |
LYKALABS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 68.3 ~ 71.01
Trading Inside opening range
Lyka Labs Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Lyka Labs Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Lyka Labs Ltd stood at 65.5% of traded volume, against a 20-day average of 66.7%.
Lyka Labs announcements: results, concalls, ratings, M&A.
Filings Lyka Labs sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Lyka Labs files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 51 documents below.
Copy of Newspaper Publication
Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Credit Rating
Lyka Labs Limited has informed the Exchange about Credit Rating
Disclosure under SEBI Takeover Regulations
Lyka Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Disclosure under SEBI Takeover Regulations
Ipca Laboratories Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Investor decks & rating reports.
Lyka Labs dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Lyka Labs has declared, sequenced by announce and record date.
Lyka Labs corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Lyka Labs Ltd: business, sector, key facts.
What Lyka Labs Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Lyka Labs Ltd operates in the Healthcare, listed as NSE: LYKALABS, BSE: 500259.
Lyka Labs Limited is an Indian pharmaceutical company with a comprehensive business model encompassing the development, manufacturing, and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Their product portfolio spans numerous therapeutic areas, demonstrating a significant presence in the Indian pharmaceutical market and beyond.
The company's manufacturing capabilities are extensive, producing a diverse array of formulations including topical treatments (emollients, steroids, antifungals, antibacterials, acne medications), pain relievers, anti-aging products, hair care solutions, and sunscreens. Beyond dermatological products, Lyka Labs manufactures products for various other therapeutic segments, such as gastroenterology, anti-infectives, and even intensive care medications, showcasing their versatility in manufacturing different dosage forms.
Lyka Labs' product offerings extend to a broad spectrum of dosage forms, including injections, creams, ointments, foams, gels, and lotions, catering to a wide range of patient needs and administration preferences. This diverse portfolio also includes nutraceuticals, indicating a focus on both pharmaceutical and health supplement markets.
A significant aspect of Lyka Labs' business is its provision of contract manufacturing services to other large pharmaceutical companies. This service extends beyond simply manufacturing; it also includes offering crucial technical assistance, encompassing manufacturing know-how, facility support, and the provision of vital technical data such as stability testing data, impurity profiles, and bioequivalence (BA/BE) clinical study data. This demonstrates a commitment to providing comprehensive support to its clients.
Finally, Lyka Labs' operations extend beyond the domestic market, as the company actively exports its products internationally, indicating a successful penetration of international markets and a growing global presence. In summary, Lyka Labs is a well-established player in the pharmaceutical industry, combining internal product development and manufacturing with a significant contract manufacturing and technical services division, all while engaging in both domestic and international markets.
Questions investors ask about Lyka Labs Ltd (LYKALABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Lyka Labs Ltd (LYKALABS)?
The current share price of Lyka Labs Ltd (LYKALABS) is ₹69.6. Today, the stock has gained by ₹0.60 (0.87%), trading in a range of ₹68.3 to ₹71.49. The stock opened at ₹68.3 with a trading volume of 30,718 shares.
02Is Lyka Labs Ltd stock a good investment for long-term?
Lyka Labs Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹248.05 crores, P/E ratio of 0.00, ROE of 0.00%, and ROCE of 9.91%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Lyka Labs Ltd stock?
The 52-week high price of Lyka Labs Ltd (LYKALABS) is ₹0, while the 52-week low is ₹0. Currently trading at ₹69.6, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Lyka Labs Ltd stock at the current price?
Whether to buy Lyka Labs Ltd stock at ₹69.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 2.69. Today's performance shows a gain of 0.87%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Lyka Labs Ltd and when is the next dividend?
Lyka Labs Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹69.6, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Lyka Labs Ltd?
Lyka Labs Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 2.69, ROE: 0.00%, ROCE: 9.91%, Dividend Yield: 0.00%, EPS: ₹-2.81, Book Value: ₹25.87, and Debt-to-Equity: 0.00. The company's market cap stands at ₹248.05 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Lyka Labs Ltd stock performing today in the market?
Lyka Labs Ltd stock opened at ₹68.3 and is currently trading at ₹69.6, showing a gain of ₹0.60 (0.87%). The intraday high is ₹71.49 and low is ₹68.3. The trading volume stands at 30,718 shares, indicating moderate market participation today.
08What is the P/E ratio of Lyka Labs Ltd and what does it indicate?
Lyka Labs Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-2.81, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Lyka Labs Ltd (LYKALABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy